Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating reiterated by investment analysts at TheStreet in a note issued to investors on Friday, American Banking and Market News reports.
The analysts wrote, “Gilead (GILD) has been reiterated by TheStreet Ratings as a buy with a ratings score of A-. The company’s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.”
Shares of Gilead Sciences (NASDAQ:GILD) opened at 68.98 on Friday. Gilead Sciences has a 1-year low of $35.68 and a 1-year high of $73.20. The stock’s 50-day moving average is $66.16 and its 200-day moving average is $59.1. The company has a market cap of $105.8 billion and a price-to-earnings ratio of 37.96.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the previous year, the company posted $1.00 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $2.00 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Argus raised their price target on shares of Gilead Sciences from $70.00 to $84.00 in a research note to investors on Friday, November 1st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Separately, analysts at Barclays raised their price target on shares of Gilead Sciences from $68.00 to $74.00 in a research note to investors on Wednesday, October 30th. They now have an “overweight” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Gilead Sciences in a research note to investors on Wednesday, October 30th. They now have a $73.00 price target on the stock. Six research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $71.70.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.